DLD Asset Management’s Neurogene NGNE Stock Holding History

DLD Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-18,965	Closed	-$1.01M	–	115
2018 Q2	$1.01M	Buy	+18,965	New	+$4.94M	0.08%	97

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

DLD Asset Management's NGNE Position: Q3 2018 in Review

DLD Asset Management sold out of Neurogene (NGNE) in Q3 2018, closing a stake of 18,995 shares — an estimated $1.12M sold.

DLD Asset Management first reported a position in NGNE in Q2 2018 and held it in 1 quarter. The position peaked at $1.01M in Q2 2018. 45 funds tracked by Wall St. Rank hold NGNE as of Q3 2018.

DLD Asset Management reported no remaining Neurogene position as of Q3 2018 after selling out during the quarter.
DLD Asset Management sold 18,995 Neurogene shares in Q3 2018, an estimated $1.12M.
DLD Asset Management first reported a position in Neurogene in Q2 2018 and held it in 1 quarter.
DLD Asset Management's Neurogene position peaked at $1.01M in Q2 2018.
45 funds tracked by Wall St. Rank held Neurogene as of Q3 2018.

Based on DLD Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.